Research-use catalog page
COA request, lot visibility, availability, and schema stay aligned.
Semaglutide is a GLP-1 receptor agonist with ~7-day half-life via albumin-binding fatty acid modification — the most extensively studied GLP-1RA, anchoring the SUSTAIN and STEP clinical programs.
Temporarily unavailable
This product is listed in the catalog, but it is not currently available for ordering. Pricing, specifications, and support details remain visible while launch availability is being finalized.
Free shipping on orders over $150
Research Supplies
Need bacteriostatic water, syringes, or an alcohol prep kit? Email us — we can bundle reconstitution supplies with your order.
Ask about a research kit →Need the COA before you order? Request it here.
In your order
Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.
The Peptific standard
Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.
Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.
How it works
Semaglutide activates GLP-1 receptors in pancreatic beta cells (insulin secretion), hypothalamus (appetite suppression), and gastrointestinal tract (gastric emptying delay). Albumin binding via C18 fatty diacid conjugate extends half-life to ~7 days. Phase III data documents 15% body weight reduction at 68 weeks (STEP-1) and cardiovascular event reduction (SUSTAIN-6).
Compound profile
Product definition
Semaglutide is a GLP-1 receptor agonist with ~7-day half-life via albumin-binding fatty acid modification — the most extensively studied GLP-1RA, anchoring the SUSTAIN and STEP clinical programs.
Semaglutide is a 31-amino-acid GLP-1 receptor agonist developed by Novo Nordisk. Its two critical modifications distinguish it from native GLP-1 and earlier GLP-1RA compounds: (1) Aib substitution at position 8 eliminates DPP-IV cleavage — the primary inactivation pathway for native GLP-1; (2) a C18 fatty diacid chain at position 26 (via a short linker) enables reversible albumin binding that dramatically extends half-life while maintaining GLP-1R selectivity and full agonism. The pharmacological research profile spans multiple programs: SUSTAIN (subcutaneous semaglutide for T2D, 7 trials), STEP (subcutaneous semaglutide for obesity, 4 Phase III trials), PIONEER (oral semaglutide for T2D), and SELECT (cardiovascular outcomes in obesity without diabetes). The breadth and scale of this dataset — across ~50,000 research participants — makes semaglutide the most comprehensively characterized GLP-1 receptor agonist in the open literature, with published pharmacokinetic, pharmacodynamic, and outcomes data across glycemic, cardiovascular, renal, hepatic, and weight endpoints.
Research audience
Semaglutide is used by researchers in metabolic disease pharmacology, GLP-1 receptor biology, obesity mechanisms, beta cell function, hepatic metabolism, and cardiovascular endocrinology. It is the reference compound for GLP-1RA class pharmacology due to the depth and scale of its published clinical and preclinical dataset.
Research context
Semaglutide was developed by Novo Nordisk through optimization of the GLP-1 analog class, drawing on the lessons of earlier GLP-1RAs (liraglutide, exenatide) to achieve weekly dosing and improved tolerability. The albumin-binding mechanism extends half-life by slowing renal filtration and proteolytic exposure while preserving the reversibility of receptor engagement. In GLP-1 receptor biology research, semaglutide is used as a pharmacological tool because of the quality of its published receptor kinetics data. The compound shows full GLP-1R agonism with sub-nanomolar EC50, making it useful for dose-response studies examining the relationship between GLP-1R occupancy and downstream signaling (cAMP, PKA, Epac, insulin secretion). In obesity and metabolic research, the STEP trials established that pharmacological GLP-1R activation via weekly injection can produce body weight reduction comparable in magnitude to metabolic surgery in some participants — a finding that has driven substantial academic investigation into the mechanisms of GLP-1R-mediated appetite suppression, including hypothalamic neural circuit research, gut-brain axis studies, and dopaminergic reward system interactions. Semaglutide is also the lead comparator in trials of next-generation compounds (tirzepatide, retatrutide, cagrilintide+semaglutide), making it the pharmacological baseline for studying incretin pharmacology advancement.
Common questions
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy
You might also want to check out these products.
Cagrilintide
Cagrilintide is a long-acting amylin analog (~7-day half-life) developed for once-weekly combination dosing with semaglutide — the most clinically advanced amylin compound, with Phase 3 REDEFINE data published.
Cagri/Sema
CagriSema is a fixed combination of cagrilintide (amylin analog) and semaglutide (GLP-1RA) studied in Phase 3 REDEFINE trials — 22.7% mean body weight reduction at 68 weeks, exceeding semaglutide-alone benchmarks.
Retatrutide
Retatrutide is a once-weekly triple GLP-1/GIP/glucagon receptor agonist — Phase 2 data showed 24.2% mean body weight reduction at 48 weeks, the highest result in obesity pharmacology Phase 2 trial history at publication.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its class, with Phase III data showing 22.5% mean body weight reduction at 72 weeks, the highest performance in obesity pharmacology trial history at publication.
$25.00
$27.00
$30.00
$25.00